Cost Plus Drugs Starts Custom Rare Disease Treatment
The Dallas factory now processes DNA-like molecules to target individual genetic mutations, marking a pivot from generic drugs.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you believe private companies can successfully lower the cost of rare disease treatments?
In 2026, Cost Plus Drugs began utilizing a Dallas manufacturing facility to produce custom treatments for patients with rare diseases. The site processes DNA-like molecules designed to target specific genetic mutations on an individual basis.
Why it matters
This initiative represents a significant expansion for Cost Plus Drugs, which spent the previous five years focused on generic chemotherapy and antifungal medications. The move aims to increase treatment access for rare disease populations who previously faced limited options.
The Dallas facility utilizes DNA-like molecules to build personalized treatments that target unique genetic mutations. This capability marks a functional departure from the company's prior five-year business model centered exclusively on generic chemotherapy and antifungal medications.
The players
Cost Plus Drugs
A pharmaceutical company that shifted from a five-year focus on generic drugs to personalized rare disease manufacturing.
Mark Cuban
The business leader who founded the company to address pricing issues in the pharmaceutical sector.
The details
The facility manufactures medicines using DNA-like molecules, which are synthetic sequences engineered to interact with the specific genetic code of a patient. These molecules act as precision tools, designed to address the unique mutations responsible for a specific rare disease. The production process requires collaboration between teams in California and the Netherlands, who develop the molecular designs before they are synthesized in the Dallas plant.
Timeline
2021-2026: Mark Cuban worked to lower generic drug costs.
2026: Custom rare disease medicines began arriving at the factory.
The Tech Race
This development follows a pattern set by the industry-wide shift toward precision therapeutics, moving from off-the-shelf generic models toward patient-specific molecular design. It marks a clear departure for Cost Plus Drugs as it enters the competitive landscape of rare disease treatment production.
This transition changes the manufacturing workflow from generic supply to custom molecular production for patients with specific genetic conditions. The availability of these therapies is tied to the internal development pipeline and remains restricted to targeted, personalized cases.
The takeaway
The move suggests a long-term shift for the company toward highly specialized, low-volume pharmaceutical production. Observers should track if this Dallas facility adds further genetic targets or expands its molecular synthesis capacity in the coming years.
Further reading
For broader context on how modern manufacturing enables precision care, see our coverage in Biotech.
Source note: This article includes information reported by STAT.
Live Poll
Do you believe private companies can successfully lower the cost of rare disease treatments?
